Liver cancer patients get chemo via implantable pump in new safety trial
NCT ID NCT04684862
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a combined pump and catheter system that delivers chemotherapy directly to the liver in adults with colorectal cancer that has spread to the liver or with bile duct cancer. The main goal is to see if the device is safe. About 100 participants will have the pump implanted and be monitored for up to 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Medtronic SynchroMed II pump connected to an Intera tapered catheter (device) delivering FUDR chemotherapy
- What this could lead to
- If this device proves safe and effective, it could offer a more targeted way to deliver chemotherapy to liver tumors, potentially reducing side effects and improving tumor control.
- What could go wrong
- This is an early safety study with no control group, so it cannot prove the device works better than standard treatment. There are risks from surgery, the pump, and the catheter connection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC TO LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- Can matching drugs to tumor genes beat biliary cancer?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
- Triple attack on bile duct cancer: chemo, targeted drug, and immunotherapy aim to make the inoperable operable